ArticleInvestigational new drugs2025

A novel anti-HER2/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs.

Huoying Huang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.